02196 FOSUN PHARMA
- 13.160
- -0.260-1.94%
FOSUN PHARMA News
FOSUN PHARMA (02196): HENLIUS has received approval for a clinical trial of HLX4 combined with surufatinib injection for the treatment of patients with advanced/metastatic solid tumors.
FOSUN PHARMA (02196) announced that its holding subsidiary HENLIUS recently received notice from the National Medical Products Administration regarding...
FOSUN PHARMA (02196.HK) holding subsidiary has obtained approval for pharmaceutical clinical trials.
On January 10, Gelonghui reported that FOSUN PHARMA (02196.HK) announced that its controlling subsidiary, Shanghai HENLIUS Biotechnology Co., Ltd. (hereinafter referred to as "the Company"), and its holding subsidiary (collectively referred to as "HENLIUS") recently received approval from the National Medical Products Administration (hereinafter referred to as "NMPA") for the use of HLX43 injection (i.e., a PD-L1 targeted antibody - novel DNA topoisomerase I inhibitor conjugate drug, registration classification: type 1 therapeutic Biological Product, hereinafter referred to as "HLX43") in combination with Surulni injection.
FOSUN PHARMA (600196.SH): The clinical trial application for injectable HLX43 has been approved.
FOSUN PHARMA (600196.SH) announced that its holding subsidiary HENLIUS Biotechnology Co., Ltd...
Guoyuan Securities 2025 CSI SWS Health Care index investment strategy report: Bullish on innovation and overseas expansion, focusing on upward fundamental segmentation tracks.
The international expansion of the pharmaceutical industry remains an essential path for our country's pharmaceutical companies in the future, and companies with strong product capabilities and channel capabilities are expected to gain an advantage.
Fosun Pharmaceutical's Unit Gets China Nod for Registration of Breast Cancer Drug
Express News | Shanghai Fosun Pharma - Drug Registration Application for Fovinaciclib Citrate Capsules of Jinzhou Avanc Pharmaceutical Accepted by Nmpa
FOSUN PHARMA (600196.SH): The pharmaceutical registration application for Vorasernib capsules has been accepted.
On January 9, Gelonghui announced that FOSUN PHARMA (600196.SH) disclosed that its holding subsidiary, Jinzhou Aohong Pharmaceutical Co., Ltd., has recently had the pharmaceutical registration application for Citric Acid Vorasentan Capsules (Project Code: FCN-437c, Registration Category: Chemical Drug Class 1; hereafter referred to as "the new drug") accepted by the National Medical Products Administration. This application is for the indication of local advanced or metastatic breast cancer in patients with hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative, and should be used in conjunction with aromatase inhibitors as the initial treatment for premenopausal, postmenopausal, and perimenopausal female breast cancer patients.
FOSUN PHARMA (600196.SH): Has not yet entered the Brain-computer Interface field.
On January 9, Gelonghui reported that FOSUN PHARMA (600196.SH) stated on the interactive platform that the company is collaborating with INSIGHTEC in the field of neurological diseases, focusing on the commercialization and clinical application of MRI-guided focused ultrasound brain treatment technology for conditions such as essential tremor and Parkinson's disease. Currently, the company has not yet entered the Brain-computer Interface field.
Here's Why Shanghai Fosun Pharmaceutical (Group) (SHSE:600196) Has A Meaningful Debt Burden
Pharmaceutical stocks have become a transitional theme at present, and the performance line may be further valued by the market.
Track the entire lifecycle of the main sector.
Shanghai Fosun Pharmaceutical (Group) Subsidiary's Cancer Drug's NDA Accepted by NMPA
Shanghai Fosun Pharma's New Cancer Drug Application Accepted
FOSUN PHARMA (600196.SH): The registration application for the injectable Raltitrexed Pharmaceutical has been accepted.
FOSUN PHARMA (600196.SH) announced that its controlling subsidiary, Gismay (Wuhan) Pharmaceutical Co., Ltd. ...
On December 30, FOSUN PHARMA (02196.HK) spent 4.94 million Hong Kong dollars to repurchase 0.35 million shares.
Gelonghui reported on December 30 that FOSUN PHARMA (02196.HK) announced that on December 30, it spent 4.94 million Hong Kong dollars to repurchase 0.35 million shares.
How is the quality and supply of Pharmaceuticals guaranteed? The National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals.
On December 26, 2024, the National Healthcare Security Administration held a symposium on centralized procurement of Pharmaceuticals, inviting representatives from the National Medical Products Administration, selected Pharmaceutical enterprises, and research Institutions to communicate and exchange views on recent societal concerns regarding quality assurance of centrally procured Pharmaceuticals and innovative development in the Industry, and to listen to opinions and suggestions.
Guangxi Wuzhou Zhongheng Group (600252.SH): A subsidiary plans to participate in the establishment of FOSUN PHARMA (Nanning) Co., Ltd.
Gelonghui reported on December 27 that Guangxi Wuzhou Zhongheng Group (600252.SH) announced that in order to meet the needs of the company's Business development, further expand the layout of the overseas market Business and enhance comprehensive competitiveness, Guangxi Wuzhou Zhongheng Group's wholly-owned subsidiary Zhongheng Yixin plans to establish a joint venture with the wholly-owned subsidiary of FOSUN PHARMA, Shanghai FOSUN PHARMA Industrial Development Co., Ltd. (referred to as "FOSUN Industrial Company"), and Nanning Industry Investment Unified Investment Group Co., Ltd. (referred to as "Unified Investment Group"). The registered capital of the joint venture is 100 million yuan, of which FOSUN Industrial Company contributes 5,100.
On December 27, FOSUN PHARMA (02196.HK) spent 2.8723 million Hong Kong dollars to repurchase 0.2045 million shares.
On December 27, Gelonghui reported that FOSUN PHARMA (02196.HK) announced the repurchase of 0.2045 million shares for HKD 2.8723 million on December 27, 2024, with a repurchase price of HKD 13.94-14.1 per share.
Shanghai Fosun Pharmaceutical Subsidiary Signs Cooperation, License Deal
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
FOSUN PHARMA (600196.SH) has signed a cooperation and licensing agreement with Palleon, intending to carry out joint clinical research on the licensed product Hanlikang.
FOSUN PHARMA (600196.SH) announced that its controlling subsidiary HENLIUS signed an agreement with Palleon...
No Data
